Navigation Links
QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy
Date:5/22/2008

surgery and prior to the first 12mg/8mg dose of Q8003IR, the baseline patient pain intensity (PI) scores averaged 6.6 out of 10 units -- with 10 being the most severe on the Numerical Pain Rating Scale. Analgesic effects as reflected in the maximum pain improvement (PI) for the 12mg/8mg dose of Q8003IR yielded a 2 unit reduction of PI (decreasing patient scores to 4.6) versus a 0.14 unit increase of PI for placebo-treated patients. Placebo patients were treated with ibuprofen, a non-opioid analgesic.

The mean time to confirmed perceptible pain relief for Q8003IR was 42 minutes compared to 4.4 hours for placebo. The duration time of analgesic effect was 6.6 hours for Q8003IR versus 2.8 hours for placebo.

The 12mg/8mgdose data demonstrated that Q8003IR was well tolerated, with a low rate of patient withdrawal (8% discontinuing use due to adverse events and 6% discontinuing use due to efficacy failure) compared to placebo (with 2% discontinuing use due to adverse events and 25% discontinuing use for efficacy failure). Only 2% of 12mg/8mg Q8003IR treated patients experienced somnolence, and no incidences of euphoria were reported. The low level of somnolence and absence of euphoria reported were unexpected outcomes compared to what is typically seen with morphine or oxycodone. The significance of these observations will need to be confirmed in future studies that provide a direct data comparison.

All patients exhibited acceptable respiratory rates with reduction in blood oxygen levels occurring in less than 2% of those on the preferred dose of Q8003IR. Typical of opioid drugs, nausea and vomiting were the most common adverse events. Of patients receiving the 12mg/8mg dose, 56% experienced mild to moderate nausea that diminished over the first few hours of treatment; no incidences of severe nausea were reported. 32% of patients reported vomiting with initial dosing (18% mild to moderate and 14% severe). 20% of patients experienced mild to moderate di
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
2. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
3. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
4. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
6. Immunosyn Corporation Releases SF-1019 Study Results
7. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
8. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/12/2014)... The Passenger Information System market is estimated to ... by 2019, at an expected CAGR of 26.5% for ... transport infrastructure in North America is well developed and ... corner of the region. The growing ridership figures in ... providers are driving the North American Passenger Information System ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The report, ... Alkyd Resins) Market by Application & Geography – Trends ... market with analysis and forecasting of market volume and ... of the derivatives separately. The market of phthalic anhydride ... in 2013 to $8,415.89 million by 2018, with a ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The fastest-growing ... for test and measurement of LTE networks continues to ... demands for smart devices have increased mobile data traffic, ... and Measurement (CT&M) market. Communications Test and Measurement equipment ... requirements. , The Communications Test and Measurement Market is ...
(Date:7/12/2014)... make exercise fun, you,ll eat less after your workout, new ... on a 1.4-mile walk and were either told it would ... were given lunch after the walk, and those who were ... chocolate pudding for dessert than those who were told it ... were given mid-afternoon snacks after their walk. Those who were ...
Breaking Medicine News(10 mins):Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2
... , , Congressman Chaka Fattah (D-PA) ... America,s healthcare system. , , WASHINGTON, Aug. 17 ... If real reform is to take place it must include a public ... airport in any major city they deliberate how they will get to their ...
... , , CHESTERFIELD, ... RELV ), a nutrition and direct selling company, today launched ... company,s line of proprietary nutritional supplements. , , ... Reliv,s breakthrough r(TM) skincare collection that combines some of the ...
... , , SAN FRANCISCO, ... leader in healthcare data management and decision support solutions ... a strategic alliance with CACTUS Software, a leading provider ... expand the capabilities and simplify the ability of healthcare ...
... , CHICAGO, Aug. 17 Presidential ... furnished two bedroom apartment to the University of Illinois Medical Center ... undergoing care at the medical center. , , ... Towers felt that this was a great way to give back ...
... PARK, N.J., Aug. 17 Managed Health Care Associates, Inc. ... joined MHA as Vice President & General Counsel. In ... all legal matters for the company, including healthcare compliance, contract ... and CFO of MHA commented "The establishment of this important ...
... Volumizing the Brow ... ... eyes change in generally predictable ways: the skin thins and becomes less elastic, brows may ... more prominent. While surgery has long been the accepted standard and offers significant benefits ...
Cached Medicine News:Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 2Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 3Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 2Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 3Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2Health News:MHA Announces Gloria Barr, Esq. as Vice President & General Counsel 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: